Company Investors Technology Careers Updates Events Contact Publications Exonate encompasses scientific excellence in everything we do Key Publications - Ophthalmology Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease. Batson J, Toop HD, Redondo C et al. ACS Chem Biol. 2017 Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina. Ved N, Hulse RP, Bestall SM, Donaldson LF, Bainbridge JW, Bates DO. Clinical Science. 2017 VEGF-A165b is cytoprotective and antiangiogenic in the retina. Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HT, Bates DO, Churchill AJ. Invest Ophthalmol Vis Sci. 2010 Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Hua J, Spee C, Kase S, Rennel ES, Magnussen AL, Qiu Y, Varey A, Dhayade S, Churchill AJ, Harper SJ, Bates DO, Hinton DR. Invest Ophthalmol Vis Sci. 2010 SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Gammons MV, Dick AD, Harper SJ, Bates DO. Invest Ophthalmol Vis Sci. 2013 Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Gammons MV, Fedorov O, Ivison D, Du C, Clark T, Hopkins C, Hagiwara M, Dick AD, Cox R, Harper SJ, Hancox JC, Knapp S, Bates DO. Invest Ophthalmol Vis Sci. 2013 Conference Abstracts- Ophthalmology EXN407, a novel topical therapeutic candidate with high retinal bioavailability for the treatment of diabetic macular oedema, inhibits ocular neovascularisation. Batson J, Toop H, Liddell S, et al. Investigative Ophthalmology & Visual Science July 2019. Targeting SRPK1 with novel potent and selective small molecule inhibitors inhibits choroidal neovascularisation through modulating VEGF-A alternative splicing. Bates DO, Toop H, Daubney J, Stewart E, Morris J, Batson J. Investigative Ophthalmology & Visual Science 2017. Novel SRPK1 inhibitors specifically target alternative splicing in human primary retinal epithelial cells. Rowlinson J, Batson J, Toop H, Allen C, Gibbons B, Babaei‐Jadidi R, Zhang J, Wearmouth S, Knapp S, Morris J, Bates D. Acta Ophthalmologica 2015. SRPK1 inhibitors as novel anti‐angiogenic therapeutics for wet age‐related macular degeneration (wAMD). Batson J, Toop H, Rowlinson J, Allen C, Gibbons B et al. Acta Ophthalmologica, 2015. LEARN ABOUT OUR TECHNOLOGY Who we are Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis) This is a key driver of disease progression in some ophthalmic conditions and cancers. Follow us on Social Media Useful links Career opportunities Technology Investors Contact Copyright © 2021 Exonate Privacy policy Designed and built by Onespacemedia